Cargando…

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy

PURPOSE: To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV). METHODS: Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or ranibizumab (n = 52, 0.5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Han Joo, Baek, Ji Seon, Lee, Dong Won, Kim, Chul Gu, Kim, Jong Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Ophthalmological Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364425/ https://www.ncbi.nlm.nih.gov/pubmed/22670070 http://dx.doi.org/10.3341/kjo.2012.26.3.157

Ejemplares similares

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
por: Jeon, Young-Joon, et al.
Publicado: (2021)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results
por: Mitamura, Yoshinori, et al.
Publicado: (2010)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
por: Kitagawa, Yorihisa, et al.
Publicado: (2022)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa, Akira, et al.
Publicado: (2017)

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
por: Kitahashi, Masayasu, et al.
Publicado: (2014)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy
por: Lee, Sun Young, et al.
Publicado: (2008)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Matsumiya, Wataru, et al.
Publicado: (2011)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai, Madoka, et al.
Publicado: (2014)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy
por: Liu, Ling, et al.
Publicado: (2015)

One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2022)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
por: Lai, Kunbei, et al.
Publicado: (2018)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020)

Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps
por: Kim, Jae Hui, et al.
Publicado: (2015)

Management of peripheral polypoidal choroidal vasculopathy with intravitreal bevacizumab and indocyanine green angiography-guided laser photocoagulation
por: Rishi, Pukhraj, et al.
Publicado: (2012)

Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up
por: Romano, Mario R, et al.
Publicado: (2010)

Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters
por: Chang, Young Suk, et al.
Publicado: (2016)

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019)

Outcome of Peripapillary Polypoidal Choroidal Vasculopathy Treatment using Combination Therapy Intravitreal Ranibizumab and Thermal Retinal Laser Photocoagulation
por: Okonkwo, Ogugua Ndubuisi, et al.
Publicado: (2023)

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
por: Peng, Yuting, et al.
Publicado: (2018)

Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi, et al.
Publicado: (2013)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Intravitreal bevacizumab associated with photodynamic therapy in a case of polypoidal choroidal vasculopathy associated with choroidal nevus: A case report
por: Rangel, Carlos M., et al.
Publicado: (2017)

Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
por: Liu, Siyin, et al.
Publicado: (2022)

Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study
por: Ghoshal, Rituparna, et al.
Publicado: (2021)

Polypoidal choroidal vasculopathy—characteristics and response to treatment with bevacizumab in caucasian patients
por: Zhalka, Fidaa El, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fu8ebdh20rcrnnbiaaf81a67vg